{
  "schema_version": "1.0",
  "type": "article",
  "title": "MSD提前押注，寶泰先拿下亞太門票",
  "url": "https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd.md",
  "lang": "zh-Hant",
  "date": "2026-10-19",
  "publish_at": "2026-10-19T09:00:00+08:00",
  "updated_at": "2026-10-19",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "寶泰生醫",
    "PT401",
    "犬心臟病",
    "基因療法",
    "MSD Animal Health"
  ],
  "summary": "犬隻黏液性二尖瓣疾病B1期確診後只能追蹤。2026年6月MSD Animal Health投資Rejuvenate Bio，寶泰生醫則早在2024年底拿下犬心臟基因療法PT401的亞太獨家權利。",
  "key_points": [
    "寶泰生醫在2024年底取得Rejuvenate Bio犬心臟基因療法（PT401，前身RJB-01）的亞太獨家開發、經銷與行銷權，並規劃泰國B1先導研究與台灣B2樞紐性臨床試驗兩條路徑。",
    "2026年6月，2025年營收約63.54億美元的MSD Animal Health參與Rejuvenate Bio的600萬美元募資並展開動物基因療法策略研發合作；公開資料未顯示MSD已買下PT401。",
    "美國FDA於2025年底完整核准Vetmedin（pimobendan）延緩B2期MMVD犬隻發生充血性心臟衰竭，主要事件中位時間由766天延長至1,228天，B1期仍缺疾病進程療法。"
  ],
  "facts": [
    {
      "claim": "MSD Animal Health 2025 年營收",
      "value": 63.54,
      "unit": "億美元",
      "as_of": "2026-02-26",
      "source": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"
    },
    {
      "claim": "BRAVECTO 產品線 2025 年銷售額",
      "value": 11,
      "unit": "億美元",
      "as_of": "2026-02-26",
      "source": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"
    },
    {
      "claim": "Rejuvenate Bio 募資金額（MSD Animal Health 參與）",
      "value": 600,
      "unit": "萬美元",
      "as_of": "2026-06",
      "source": "https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health"
    },
    {
      "claim": "寶泰生醫取得犬心臟基因療法亞太獨家權利時間",
      "value": "2024 年底",
      "unit": "時間",
      "as_of": "2024-12",
      "source": "https://www.taiwan-healthcare.org/en/news-detail?id=0socwy3nnjfogkkr"
    },
    {
      "claim": "MMVD 占北美犬心臟病病例比例",
      "value": 75,
      "unit": "%",
      "as_of": "2019",
      "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6524084/"
    },
    {
      "claim": "全球獸醫心臟醫療市場 2025 年規模",
      "value": 35.6,
      "unit": "億美元",
      "as_of": "2025",
      "source": "https://www.novaoneadvisor.com/report/veterinary-cardiology-market"
    },
    {
      "claim": "全球獸醫心臟醫療市場 2035 年預估規模",
      "value": 80,
      "unit": "億美元",
      "as_of": "2035",
      "source": "https://www.novaoneadvisor.com/report/veterinary-cardiology-market"
    },
    {
      "claim": "亞太獸醫心臟醫療市場 2025 年規模",
      "value": 6.37,
      "unit": "億美元",
      "as_of": "2025",
      "source": "https://www.grandviewresearch.com/horizon/outlook/veterinary-cardiology-market/asia-pacific"
    },
    {
      "claim": "全球伴侶動物心臟藥物市場 2033 年預估",
      "value": 37.3,
      "unit": "億美元",
      "as_of": "2033",
      "source": "https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report"
    },
    {
      "claim": "亞太伴侶動物心臟藥物市場 2033 年預估",
      "value": 8.518,
      "unit": "億美元",
      "as_of": "2033",
      "source": "https://www.grandviewresearch.com/horizon/outlook/companion-animal-cardiac-drugs-market/asia-pacific"
    },
    {
      "claim": "Pimobendan 2024 年占全球伴侶動物心臟藥物市場比例",
      "value": 41.17,
      "unit": "%",
      "as_of": "2024",
      "source": "https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report"
    },
    {
      "claim": "EPIC 研究主要事件中位時間（pimobendan 組）",
      "value": 1228,
      "unit": "天",
      "as_of": "2025",
      "source": "https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs"
    },
    {
      "claim": "EPIC 研究主要事件中位時間（安慰劑組）",
      "value": 766,
      "unit": "天",
      "as_of": "2025",
      "source": "https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs"
    },
    {
      "claim": "Rejuvenate Bio RJB-01 犬先導安全研究犬數",
      "value": 18,
      "unit": "隻",
      "as_of": "2023",
      "source": "https://www.businesswire.com/news/home/20230518005611/en/Rejuvenate-Bio-Announces-Data-for-Gene-Therapy-RJB-01-in-Mitral-Valve-Disease-at-2023-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT"
    },
    {
      "claim": "MSD Animal Health 擴建美國設施投資",
      "value": 8.95,
      "unit": "億美元",
      "as_of": "2026-02-26",
      "source": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"
    }
  ],
  "sections": [
    "走向80億美元的市場裡，最安靜的缺口是B1期",
    "Pimobendan先證明：犬心臟病能長出大產品",
    "PT401想把治療往前移，也把健康時間拉長",
    "PT401能拿多少市場？先把情境換算成犬隻數",
    "MSD為什麼提早進場？答案藏在BRAVECTO的11億美元",
    "MSD進場之前，寶泰已先拿到亞太位置",
    "寶泰能否重估，要過四道資料關卡",
    "結論：第一個心臟基因療法重磅產品，可能戴著項圈走出診間",
    "參考資料"
  ],
  "references": [
    {
      "title": "Merck",
      "source": "2025 Form 10-K：Animal Health營收、BRAVECTO銷售與全球營運資料",
      "date": "2026-10-08",
      "url": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"
    },
    {
      "title": "Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health",
      "source": "Rejuvenate Bio",
      "date": "2026-10-08",
      "url": "https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health"
    },
    {
      "title": "Breakthrough in Pet Healthcare Across Asia-Pacific: Protect Biotech Partners with Rejuvenate Bio",
      "source": "Healthcare+ B2B",
      "date": "2026-10-08",
      "url": "https://www.taiwan-healthcare.org/en/news-detail?id=0socwy3nnjfogkkr"
    },
    {
      "title": "PT401泰國朱拉隆功大學B1期MMVD犬隻先導試驗公告",
      "source": "寶泰生醫",
      "date": "2026-10-08",
      "url": "https://www.protectvac.com/en/news-detail.html?id=43"
    },
    {
      "title": "寶泰生醫PT401基因療法獲國際大廠認可 與默沙東動物保健達成戰略合作",
      "source": "protectvac.com",
      "date": "2026-10-08",
      "url": "https://www.protectvac.com/news-detail.html?id=43"
    },
    {
      "title": "ACVIM Consensus Guidelines for the Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs",
      "source": "Journal of Veterinary Internal Medicine",
      "date": "2026-10-08",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6524084/"
    },
    {
      "title": "Veterinary Cardiology Market Size, Share & Trends Analysis Report, 2026–2035",
      "source": "Nova One Advisor",
      "date": "2026-10-08",
      "url": "https://www.novaoneadvisor.com/report/veterinary-cardiology-market"
    },
    {
      "title": "Asia Pacific Veterinary Cardiology Market Size & Outlook",
      "source": "Grand View Research",
      "date": "2026-10-08",
      "url": "https://www.grandviewresearch.com/horizon/outlook/veterinary-cardiology-market/asia-pacific"
    },
    {
      "title": "Companion Animal Cardiac Drugs Market Size, Share & Trends Analysis Report, 2033",
      "source": "Grand View Research",
      "date": "2026-10-08",
      "url": "https://www.grandviewresearch.com/industry-analysis/companion-animal-cardiac-drugs-market-report"
    },
    {
      "title": "Asia Pacific Companion Animal Cardiac Drugs Market Size & Outlook, 2033",
      "source": "Grand View Research",
      "date": "2026-10-08",
      "url": "https://www.grandviewresearch.com/horizon/outlook/companion-animal-cardiac-drugs-market/asia-pacific"
    },
    {
      "title": "FDA Approves First Drug to Delay Congestive Heart Failure in Dogs",
      "source": "U.S. Food and Drug Administration",
      "date": "2026-10-08",
      "url": "https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-delay-congestive-heart-failure-dogs"
    },
    {
      "title": "Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study",
      "source": "Journal of Veterinary Internal Medicine",
      "date": "2026-10-08",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27678080/"
    },
    {
      "title": "犬心臟病雙基因AAV基因療法PT401技術資料",
      "source": "國家新創獎",
      "date": "2026-10-08",
      "url": "https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCID=0t8yaf32esblr8rc&REFDOCTYPID=0mge2pv6fmqrxoa1&num=1"
    },
    {
      "title": "Rejuvenate Bio Announces Data for Gene Therapy RJB-01 in Mitral Valve Disease at the 2023 ASGCT Annual Meeting",
      "source": "Business Wire",
      "date": "2026-10-08",
      "url": "https://www.businesswire.com/news/home/20230518005611/en/Rejuvenate-Bio-Announces-Data-for-Gene-Therapy-RJB-01-in-Mitral-Valve-Disease-at-2023-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT"
    },
    {
      "title": "Merck & Co., Inc. 2025 Form 10-K and Full-Year Financial Results",
      "source": "Merck",
      "date": "2026-10-08",
      "url": "https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf"
    }
  ],
  "images": [
    {
      "alt": "圖1. 從犬MMVD的B1治療空白出發，圖中整理PT401的一次／低頻介入概念，以及Rejuvenate Bio與寶泰的",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-01.png"
    },
    {
      "alt": "圖2. 犬MMVD市場、疾病分期與B1治療空白。病例、診斷與追蹤已經存在，新療法要回答的，是能否在心臟擴大以前安全介入。",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-02.png"
    },
    {
      "alt": "圖3. EPIC Study與FDA核准讓Pimobendan成為B2期核心治療，也證明「延後疾病事件」能在犬心臟病形成",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-03.png"
    },
    {
      "alt": "圖4. PT401以雙基因AAV嘗試把介入窗口移到高風險B1／早期B2，產品輪廓建立在一次／低頻給藥、持續表達與更長治療",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-04.png"
    },
    {
      "alt": "圖5. 寶泰PT401未來亞太與全球心臟藥物市場滲透分析。",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-05.png"
    },
    {
      "alt": "圖6. MSD為何入局：BRAVECTO把低頻給藥做成11億美元產品線，這項經驗說明MSD為何熟悉長效、獸醫介入與持續追",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-06.png"
    },
    {
      "alt": "圖7. 三方合作背後戰略意義與佈局：Rejuvenate Bio提供技術、寶泰先取得亞太獨家權利並推進泰國B1與台灣後續",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-07.png"
    },
    {
      "alt": "圖8. 寶泰的下一段價值取決於四層證據：亞洲試驗運轉、安全與持續表達、疾病進程改變，以及能否進入全球產品化。",
      "url": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/figure-08.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/protect-pt401-canine-heart-gene-therapy-msd/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-19）。MSD提前押注，寶泰先拿下亞太門票。https://drugnews.com.tw/articles/2026-10-19-protect-pt401-canine-heart-gene-therapy-msd.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {}
}